Tag: Drug Patents

Nativa won a patent dispute with Bristol-Myers Squibb with regard to dasatinib

The Arbitration Court of the Moscow region decided to fully reject the claims filed by Bristol-Myers Squibb Holdings Ireland against Nativa LLC under the case No. A41-87845/2017.

Targovax secures a patent from the European Patent Office

Targovax, is a Norwegian clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, announced that the European Patent Office had granted European Patent.

Plantform Corporation received a patent from the European Patent Office

PlantForm Corporation has been granted a patent by the European Patent Office – Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments – under patent No. 2355849.

Nativa received a license to use dependent invention

On June 1, 2018, the Moscow Arbitration Court satisfied the claim to issue a license for the use of a Celgene’s patent in respect of dependent invention, which Nativa LLC plans to use in the manufacturing of medicinal product.

Nativa won in court its patent dispute with Bayer

The Arbitration Court of Moscow region decided to reject the claim of Bayer (Bayer Healthcare LLC) to Nativa, a Russian company, aimed at recognizing and stopping the actions that violate the exclusive rights of the plaintiff.

Ruspharmtech has received U.S. patent for cancer drug alofanib

Russian Pharmaceutical Technologies (Ruspharmtech, a SKOLKOVO resident) has increased the commercial value of its patent portfolio by obtaining a US patent.

11028 foreign and 5285 local patents are registered in the Russian Federation

20 decisions on disputes related to patent rights in the area of pharmaceuticals have been made in 10 months of 2017